What’s the latest on antiviral drugs in Australia

What’s the latest on antiviral drugs in Australia


The ongoing COVID-19 pandemic has led to multiple waves of infections worldwide. As the virus continues to evolve, the search for effective treatments remains crucial. Antiviral drugs have shown promise in combating the virus, and Australia has been actively monitoring and approving their use. In this article, we will discuss the latest updates on antiviral drugs and who is eligible to receive them in Australia.

Latest Updates on Antiviral Drugs

Antiviral drugs are medications specifically designed to target and inhibit the replication of viruses within the body. They can help reduce the severity of symptoms, shorten the duration of illness, and potentially prevent hospitalization or death.

In recent months, several antiviral drugs have gained attention for their potential effectiveness against COVID-19. These include:

  • nMolnupiravir: This oral antiviral drug has shown promising results in reducing the risk of hospitalization and death in COVID-19 patients. It is currently undergoing clinical trials in Australia.
  • nPaxlovid: Another oral antiviral drug, Paxlovid, has demonstrated efficacy in reducing the risk of severe illness and hospitalization. It has received emergency use authorization in some countries and is being evaluated for use in Australia.
  • nRemdesivir: Although not a new drug, Remdesivir has been used to treat COVID-19 patients in severe conditions. It has shown some effectiveness in reducing recovery time and preventing disease progression.

Eligibility for Antiviral Drugs in Australia

The eligibility criteria for receiving antiviral drugs in Australia may vary based on factors such as the drug’s availability, clinical guidelines, and the severity of the patient’s condition. Currently, the Australian government has outlined the following eligibility criteria:

  • Patients must have tested positive for COVID-19.
  • Patients must be at high risk of developing severe illness or complications due to COVID-19.
  • Patients must meet specific clinical criteria, which may include factors such as age, underlying health conditions, and immunocompromised status.

It is important to note that eligibility criteria may change as new evidence emerges and more antiviral drugs become available.


As the COVID-19 pandemic continues to impact communities worldwide, the search for effective treatments remains a top priority. Antiviral drugs have shown promise in reducing the severity of illness and preventing hospitalization. In Australia, ongoing research and clinical trials are evaluating the effectiveness of various antiviral drugs, including Molnupiravir and Paxlovid. Eligibility for these drugs is determined based on specific criteria, with a focus on high-risk individuals. It is crucial to stay updated with the latest information from health authorities regarding the availability and eligibility for antiviral drugs in Australia.